• Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19

      Boras, Britton; Jones, Rhys M; Anson, Brandon J; Arenson, Dan; Aschenbrenner, Lisa; Bakowski, Malina A; Beutler, Nathan; Binder, Joseph; Chen, Emily; Eng, Heather; et al. (Springer Nature, 2021-10-18)
      COVID-19 caused by the SARS-CoV-2 virus has become a global pandemic. 3CL protease is a virally encoded protein that is essential across a broad spectrum of coronaviruses with no close human analogs. PF-00835231, a 3CL protease inhibitor, has exhibited potent in vitro antiviral activity against SARS-CoV-2 as a single agent. Here we report, the design and characterization of a phosphate prodrug PF-07304814 to enable the delivery and projected sustained systemic exposure in human of PF-00835231 to inhibit coronavirus family 3CL protease activity with selectivity over human host protease targets. Furthermore, we show that PF-00835231 has additive/synergistic activity in combination with remdesivir. We present the ADME, safety, in vitro, and in vivo antiviral activity data that supports the clinical evaluation of PF-07304814 as a potential COVID-19 treatment.